Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target

Clinical Cancer Research

Volumn 12, Issue 11 I, 2006, Pages 3257-3264

  Ito, Hirotaka ^a,d   Funahashi, Shin Ichi ^a,d   Yamauchi, Naoko ^e   Shibahara, Junji ^e   Midorikawa, Yutaka ^a,b   Kawai, Shigeto ^d   Kinoshita, Yasuko ^d   Watanabe, Akira ^a   Hippo, Yoshitaka ^a   Ohtomo, Toshihiko ^d   Iwanari, Hiroko ^c   Nakajima, Atsushi ^e   Makuuchi, Masatoshi ^b   Fukayama, Masashi ^e   Hirata, Yuichi ^d   Hamakubo, Takao ^a   Kodama, Tatsuhiko ^a   Tsuchiya, Masayuki ^d   Aburatani, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Perseus Proteomics   (Japan)

^d CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^e YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PROTEIN ROBO1; RNA; ROUNDABOUT RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOTOXICITY TESTS, IMMUNOLOGIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; NERVE TISSUE PROTEINS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 33745212839     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2787     Document Type: Article

References (25)

1. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609-19.
2. Carter P, Presta L, Gorman C, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
3. Carter P, Smith L, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 2004;11:659-87.
4. 2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-23
5. Chen X, Cheung ST, So S, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002;13:1929-39.
6. Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001;61:2129-37.
7. Smith MW, Yue ZN, Geiss GK, et al. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res 2003;63:859-64
8. Xu XR, Huang J, Xu ZG, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci U S A 2001;98:15089-94
9. Midorikawa Y, Ishikawa S, Iwanari H, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003;103:455-65.
10. Chuma M, Sakamoto M, Yamazaki K, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003;37:198-207.
11. Brose K, Bland KS, Wang KH, et al. Slit proteins bind Robo receptors and have an evolutionary conserved role in repulsive axon guidance. Cell 1999;96:795-806.
12. Kidd T, Brose K, Mitchell KJ, et al. Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionary conserved guidance receptors. Cell 1998;92:205-15.
13. Kidd T, Bland KS, Goodman CS. Slit is the midline repellent for the robo receptor in Drosophila. Cell 1999;96:785-94.
14. Li HS, Chen JH, Wu W, et al. Vertebrate slit, a secreted ligand for the transmembrane protein roundabout, is a repellent for olfactory bulb axons. Cell 1999;96:807-18.
15. Dallol A, Forgacs E, Martinez A, et al. Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers. Oncogene 2002;21:3020-8.
16. Watanabe A, Hippo Y, Taniguchi H, et al. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 2003;63:8629-33.
17. Midorikawa Y, Tsutsumi S, Taniguchi H, et al. Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis Jpn J Cancer Res 2002;93:636-43.
18. Hippo Y, Taniguchi H, Tsutsumi S, et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 2002;62:233-40.
19. Tanaka T, Takeno T, Watanabe Y, et al. The generation of monoclonal antibodies against human peroxisome proliferator-activated receptors (PPARs). J Atheroscler Thromb 2002;9:233-42.
20. Watanabe Y, Tanaka T, Uchiyama Y, et al. Establishment of a monoclonal antibody for human LXRalpha: detection of LXRalpha protein expression in human macrophages. Nucl Recept 2003;1:1.
21. Watanabe Y, Jiang S, Takabe W, et al. Expression of the LXRalpha protein in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2005;25:622-7.
22. Dallol A, Da Silva NF, Viacava P, et al. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res 2002;62:5874-80.
23. Dallol A, Morton D, Maher ER, Latif F. SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells. Cancer Res 2003;63:1054-8
24. Xian J, Aitchison A, Bobrow L, et al. Targeted disruption of the 3p12 gene, Dutt1/Robo1, predisposes mice to lung adenocarcinomas and lymphomas with methylation of the gene promoter. Cancer Res 2004;64:6432-7.
25. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.